The efficacy and safety of the low-thalidomide dose CTD (cyclophosphamide, thalidomide, dexamethasone) regimen in patients with multiple myeloma—A report by the Polish Myeloma Study Group

详细信息    查看全文

• 作者：Anna Dmoszynska ; Adam Walter-Croneck ; Iwona Hus ; Norbert Grzasko ; Joanna Manko ; Wieslaw Wiktor Jedrzejczak ; Grzegorz Charlinski ; Lidia Usnarska-Zubkiewicz ; Aleks ; er Skotnicki ; Teresa Wolska-Smolen ; Ja
• 关键词：Multiple myeloma ; CTD ; Thalidomide ; Cyclophosphamide ; Dexamethasone ; Response rates ; Survival
• 刊名：Leukemia Research
• 出版年：2010
• 出版时间：October 2010
• 年：2010
• 卷：34
• 期：10
• 页码：1330-1335
• 全文大小：297 K

文摘

Multiple myeloma (MM) remains an incurable disease, but response rates to new drugs are promising, offering the majority of patients a significant prolongation of overall survival.

The objective of this study was to evaluate time to progression (TTP), event-free survival (EFS), and overall survival (OS) in MM patients treated with a combination of cyclophosphamide (CY), thalidomide (THAL) and dexamethasone (DEX).

This study included 132 untreated and relapsing/resistant patients treated with the low-thalidomide dose CTD regimen. The patients received CY 500 mg/m² i.v. or 625 mg/m² orally at day 1, THAL 100 mg/day á la longue and DEX 20 mg/day at days 1–4 and 8–11, every 28 days. Patients received 6–9 cycles; ORR by 3 months was 59.1 % , by 6 months 65.6 % and by 9 months 75.6 % . In patients responding to CTD therapy (CR, nCR, PR), the probability of survival for 20 months was 89.3 % . The outpatient low-thalidomide dose CTD regimen is well tolerated and produces a significant response rate both in untreated and relapsing/resistant MM patients.